CLDI Key Statistics, Chart & Performance
The current stock price of CLDI is 1.02 USD. In the past month the price decreased by -12.82%. In the past year, price decreased by -88.79%.
CLDI Technical Analysis
CLDI Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLDI Forecast & Estimates
CLDI Ownership
CLDI Latest News, Press Relases and Analysis
About CLDI
Company Profile
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Company Info
CALIDI BIOTHERAPEUTICS INC
4475 Executive Drive, Suite 200
San Diego CALIFORNIA US
Employees: 28
Phone: 18587949600
CALIDI BIOTHERAPEUTICS INC / CLDI FAQ
What does CALIDI BIOTHERAPEUTICS INC do?
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
What is the current price of CLDI stock?
The current stock price of CLDI is 1.02 USD. The price decreased by -2.86% in the last trading session.
Does CALIDI BIOTHERAPEUTICS INC pay dividends?
CLDI does not pay a dividend.
What is the ChartMill rating of CALIDI BIOTHERAPEUTICS INC stock?
CLDI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What sector and industry does CALIDI BIOTHERAPEUTICS INC belong to?
CALIDI BIOTHERAPEUTICS INC (CLDI) operates in the Health Care sector and the Biotechnology industry.
How many employees does CALIDI BIOTHERAPEUTICS INC have?
CALIDI BIOTHERAPEUTICS INC (CLDI) currently has 28 employees.
What is the market capitalization of CLDI stock?
CALIDI BIOTHERAPEUTICS INC (CLDI) has a market capitalization of 7.31M USD. This makes CLDI a Nano Cap stock.